JCO Journals
@jco-asco.bsky.social
The latest advances in cancer research to improve the lives of patients.
Exciting news! Fabio Ynoe de Moraes, MD, PhD, MBA, of Queen’s University has been named Deputy Editor of JCO Global Oncology.
Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide.
Join us in congratulating Dr. Moraes!
#GlobalOncology
Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide.
Join us in congratulating Dr. Moraes!
#GlobalOncology
January 29, 2026 at 5:00 PM
Exciting news! Fabio Ynoe de Moraes, MD, PhD, MBA, of Queen’s University has been named Deputy Editor of JCO Global Oncology.
Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide.
Join us in congratulating Dr. Moraes!
#GlobalOncology
Dr. Moraes’ leadership will drive #JCOGO’s mission to improve cancer care access and equity worldwide.
Join us in congratulating Dr. Moraes!
#GlobalOncology
Reposted by JCO Journals
#Telehealth has been a huge boon to oncology: save pts time, see people who might not be able to travel.
Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts?
A: Largely, no! Similar communication, slight ⬆️ appts.
ascopubs.org/doi/full/10....
Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts?
A: Largely, no! Similar communication, slight ⬆️ appts.
ascopubs.org/doi/full/10....
January 29, 2026 at 4:23 AM
#Telehealth has been a huge boon to oncology: save pts time, see people who might not be able to travel.
Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts?
A: Largely, no! Similar communication, slight ⬆️ appts.
ascopubs.org/doi/full/10....
Q in new study @jco-asco.bsky.social: is "webside manner" affecting quality? Are we just adding extra appts?
A: Largely, no! Similar communication, slight ⬆️ appts.
ascopubs.org/doi/full/10....
We are thrilled to welcome Dr. Hsu as the new Editor-in-Chief of the ASCO Educational Book. A leader at UCSF and the San Francisco VA, Dr. Hsu aims to evolve the journal by embracing new formats to contextualize emerging oncology discoveries. Welcome!
January 28, 2026 at 2:00 PM
We are thrilled to welcome Dr. Hsu as the new Editor-in-Chief of the ASCO Educational Book. A leader at UCSF and the San Francisco VA, Dr. Hsu aims to evolve the journal by embracing new formats to contextualize emerging oncology discoveries. Welcome!
In the latest #JCO Cancer Stories with host Dr. @mikkaelsekeres.bsky.social
Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children.
Listen here: https://bit.ly/3ZxVYD9
#ArtOfOncology
Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children.
Listen here: https://bit.ly/3ZxVYD9
#ArtOfOncology
January 27, 2026 at 6:01 PM
In the latest #JCO Cancer Stories with host Dr. @mikkaelsekeres.bsky.social
Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children.
Listen here: https://bit.ly/3ZxVYD9
#ArtOfOncology
Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children.
Listen here: https://bit.ly/3ZxVYD9
#ArtOfOncology
When an oncologist leaves a rural community, the vacancy is more than a line item on a HR report. A new #JCOOP study explores the repercussions of specialist scarcity.
Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...
Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...
January 23, 2026 at 9:22 PM
When an oncologist leaves a rural community, the vacancy is more than a line item on a HR report. A new #JCOOP study explores the repercussions of specialist scarcity.
Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...
Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...
New @ascocancer.bsky.social mCRPC living guideline updated recommendations for systemic therapy are here! For patients w/ visceral metastases (lung/liver), enzalutamide or docetaxel is advised, regardless of HRR status.
Stay current on mCRPC care: brnw.ch/21wZfuI
Stay current on mCRPC care: brnw.ch/21wZfuI
January 20, 2026 at 9:47 PM
New @ascocancer.bsky.social mCRPC living guideline updated recommendations for systemic therapy are here! For patients w/ visceral metastases (lung/liver), enzalutamide or docetaxel is advised, regardless of HRR status.
Stay current on mCRPC care: brnw.ch/21wZfuI
Stay current on mCRPC care: brnw.ch/21wZfuI
Check out JCO Precision Oncology's new TAPUR Study Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry. Learn more: brnw.ch/21wZ9I0
January 16, 2026 at 9:11 PM
Check out JCO Precision Oncology's new TAPUR Study Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry. Learn more: brnw.ch/21wZ9I0
Reposted by JCO Journals
Here is our publication in @jco-asco.bsky.social! We describe how common medications impact immunotherapy, how this affects practice and patients today, and outline ways to leverage this knowledge toward improved patient as well as our understanding of tumor immunology.
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors
ascopubs.org
January 12, 2026 at 3:56 PM
Here is our publication in @jco-asco.bsky.social! We describe how common medications impact immunotherapy, how this affects practice and patients today, and outline ways to leverage this knowledge toward improved patient as well as our understanding of tumor immunology.
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Attending ASCO #GI26? Join the Pathways to Publication Luncheon to meet the JCO Journals editorial team.
Get tips on peer review & publishing your manuscript. Limited space—first come, first served!
📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005
Get tips on peer review & publishing your manuscript. Limited space—first come, first served!
📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005
January 7, 2026 at 4:42 PM
Attending ASCO #GI26? Join the Pathways to Publication Luncheon to meet the JCO Journals editorial team.
Get tips on peer review & publishing your manuscript. Limited space—first come, first served!
📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005
Get tips on peer review & publishing your manuscript. Limited space—first come, first served!
📅 Jan 9 | 11:45 AM PT | Level 3, Room 3005
Just published in #JCO, @jmikhaelmd.bsky.social & @lisakhicks.bsky.social introduce a new @ascocancer.bsky.social living guideline w/ updated recommendations for multiple myeloma therapy in differing variants and pt populations.
Learn more: brnw.ch/21wYSoe
Learn more: brnw.ch/21wYSoe
January 6, 2026 at 9:09 PM
Just published in #JCO, @jmikhaelmd.bsky.social & @lisakhicks.bsky.social introduce a new @ascocancer.bsky.social living guideline w/ updated recommendations for multiple myeloma therapy in differing variants and pt populations.
Learn more: brnw.ch/21wYSoe
Learn more: brnw.ch/21wYSoe
Patil et al’s phase II study of seribantumab in tumors harboring NRG1 fusions supports the anti-tumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions.
Read the full article. ascopubs.org/doi/abs/10.1...
Read the full article. ascopubs.org/doi/abs/10.1...
December 23, 2025 at 11:03 PM
Patil et al’s phase II study of seribantumab in tumors harboring NRG1 fusions supports the anti-tumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions.
Read the full article. ascopubs.org/doi/abs/10.1...
Read the full article. ascopubs.org/doi/abs/10.1...
Nassar et al’s study demonstrates high concordance of Recurrence Score® (RS) results between paired core needle biopsy (CNB) and surgical excision (SE) samples, which supports use of CNB for Oncotype DX® testing.
Read the full article. ascopubs.org/doi/abs/10.1...
#BreastCancer #bcsm
Read the full article. ascopubs.org/doi/abs/10.1...
#BreastCancer #bcsm
December 23, 2025 at 7:46 PM
Nassar et al’s study demonstrates high concordance of Recurrence Score® (RS) results between paired core needle biopsy (CNB) and surgical excision (SE) samples, which supports use of CNB for Oncotype DX® testing.
Read the full article. ascopubs.org/doi/abs/10.1...
#BreastCancer #bcsm
Read the full article. ascopubs.org/doi/abs/10.1...
#BreastCancer #bcsm
Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology with host @mikkaelsekeres.bsky.social.
In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent.
🎧: ascopubs.org/do/smell-sce...
In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent.
🎧: ascopubs.org/do/smell-sce...
December 16, 2025 at 6:53 PM
Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology with host @mikkaelsekeres.bsky.social.
In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent.
🎧: ascopubs.org/do/smell-sce...
In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent.
🎧: ascopubs.org/do/smell-sce...
Simultaneous publication at #SABCS25! Horimoto et al.'s real-world data explores the clinical relevance of HER2 mutations in the efficacy of Trastuzumab Deruxtecan for HER2-low metastatic breast cancer.
👉 See the analysis: ascopubs.org/doi/abs/10.1...
#BreastCancer
👉 See the analysis: ascopubs.org/doi/abs/10.1...
#BreastCancer
December 16, 2025 at 3:39 PM
Simultaneous publication at #SABCS25! Horimoto et al.'s real-world data explores the clinical relevance of HER2 mutations in the efficacy of Trastuzumab Deruxtecan for HER2-low metastatic breast cancer.
👉 See the analysis: ascopubs.org/doi/abs/10.1...
#BreastCancer
👉 See the analysis: ascopubs.org/doi/abs/10.1...
#BreastCancer
🚨 HER2+ MBC Maintenance News! 🚨
The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance.
👉 See the results: ascopubs.org/doi/abs/10.1...
#HER2Positive #BreastCancer
The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance.
👉 See the results: ascopubs.org/doi/abs/10.1...
#HER2Positive #BreastCancer
December 16, 2025 at 3:38 PM
🚨 HER2+ MBC Maintenance News! 🚨
The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance.
👉 See the results: ascopubs.org/doi/abs/10.1...
#HER2Positive #BreastCancer
The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance.
👉 See the results: ascopubs.org/doi/abs/10.1...
#HER2Positive #BreastCancer
🎧 New #JCOAfterHours episode! Dr. Davide Soldato sits down with Dr. Andrea Necchi & Dr. Ashish Kamat to discuss their @ascocancer.bsky.social article on evolving end points for non-operative #MIBC trials and bladder-sparing strategies.
Listen here: ascopubs.org/do/milan-con...
Listen here: ascopubs.org/do/milan-con...
Milan Consensus Endpoints for Bladder Preservation in MIBC | Podcast | ASCO Publications
Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article
ascopubs.org
December 15, 2025 at 8:22 PM
🎧 New #JCOAfterHours episode! Dr. Davide Soldato sits down with Dr. Andrea Necchi & Dr. Ashish Kamat to discuss their @ascocancer.bsky.social article on evolving end points for non-operative #MIBC trials and bladder-sparing strategies.
Listen here: ascopubs.org/do/milan-con...
Listen here: ascopubs.org/do/milan-con...
New data may reshape early-stage Triple-Negative Breast Cancer (TNBC) care!
Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane.
👉 Read the results: ascopubs.org/doi/abs/10.1...
#TNBC #BreastCancer
Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane.
👉 Read the results: ascopubs.org/doi/abs/10.1...
#TNBC #BreastCancer
December 12, 2025 at 7:04 PM
New data may reshape early-stage Triple-Negative Breast Cancer (TNBC) care!
Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane.
👉 Read the results: ascopubs.org/doi/abs/10.1...
#TNBC #BreastCancer
Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane.
👉 Read the results: ascopubs.org/doi/abs/10.1...
#TNBC #BreastCancer
🚨 NEW DATA ALERT! 🚨 The Phase III BRUIN CLL-313 trial (Pirtobrutinib vs. BR) in untreated CLL/SLL was presented for simultaneous publication at #ASH25! You won't want to miss this!
Learn more: ascopubs.org/doi/abs/10.1...
#CLL #SLL
Learn more: ascopubs.org/doi/abs/10.1...
#CLL #SLL
December 12, 2025 at 7:01 PM
🚨 NEW DATA ALERT! 🚨 The Phase III BRUIN CLL-313 trial (Pirtobrutinib vs. BR) in untreated CLL/SLL was presented for simultaneous publication at #ASH25! You won't want to miss this!
Learn more: ascopubs.org/doi/abs/10.1...
#CLL #SLL
Learn more: ascopubs.org/doi/abs/10.1...
#CLL #SLL
Reposted by JCO Journals
“Multidisciplinary care for a patient who's diagnosed with cancer while pregnant is essential.”
In this “Science in Seconds,” Dr. Ann Partridge & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @jco-asco.bsky.social: brnw.ch/21wYhKr
In this “Science in Seconds,” Dr. Ann Partridge & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @jco-asco.bsky.social: brnw.ch/21wYhKr
December 11, 2025 at 9:13 PM
“Multidisciplinary care for a patient who's diagnosed with cancer while pregnant is essential.”
In this “Science in Seconds,” Dr. Ann Partridge & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @jco-asco.bsky.social: brnw.ch/21wYhKr
In this “Science in Seconds,” Dr. Ann Partridge & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @jco-asco.bsky.social: brnw.ch/21wYhKr
The first-ever Phase III randomized showdown is here! See results of pirtobrutinib vs. ibrutinib in treatment-naïve and R/R patients. Is the non-covalent BTKi the game-changer we’ve waited for? #ASH25 simultaneous publication with Woyach et al. is LIVE: brnw.ch/21wYbdz
December 8, 2025 at 4:46 PM
The first-ever Phase III randomized showdown is here! See results of pirtobrutinib vs. ibrutinib in treatment-naïve and R/R patients. Is the non-covalent BTKi the game-changer we’ve waited for? #ASH25 simultaneous publication with Woyach et al. is LIVE: brnw.ch/21wYbdz
The new AL International Staging System (AL-ISS) is here, defining Stage IIIC as an ultra-poor risk. Simultaneous publication at #ASH25! This is a major step for diagnosis and patient care.
👉 Read the full abstract: brnw.ch/21wYb73
#ALamyloidosis #Hematology
👉 Read the full abstract: brnw.ch/21wYb73
#ALamyloidosis #Hematology
December 8, 2025 at 3:43 PM
The new AL International Staging System (AL-ISS) is here, defining Stage IIIC as an ultra-poor risk. Simultaneous publication at #ASH25! This is a major step for diagnosis and patient care.
👉 Read the full abstract: brnw.ch/21wYb73
#ALamyloidosis #Hematology
👉 Read the full abstract: brnw.ch/21wYb73
#ALamyloidosis #Hematology
Pennsylvania Farmers & Skin Health: Unpacking the link between specific agricultural practices and melanoma incidence in the Keystone State.
Learn more: brnw.ch/21wXMUK
Learn more: brnw.ch/21wXMUK
November 24, 2025 at 9:30 PM
Pennsylvania Farmers & Skin Health: Unpacking the link between specific agricultural practices and melanoma incidence in the Keystone State.
Learn more: brnw.ch/21wXMUK
Learn more: brnw.ch/21wXMUK
Reposted by JCO Journals
"I was lucky. I had good insurance, I lived in LA, I was treated at 4 big cancer centers.
I speak to patients who if they don't go to work today, they don't get a paycheck. They can't miss a day to travel 8 hours to go see a specialist."
🎙️New @ascocancer.bsky.social @jco-asco.bsky.social podcast:
I speak to patients who if they don't go to work today, they don't get a paycheck. They can't miss a day to travel 8 hours to go see a specialist."
🎙️New @ascocancer.bsky.social @jco-asco.bsky.social podcast:
Improving CAR-T Access | Podcast | ASCO Publications
Dr. Chino talks with Dr. Navneet Majhail and patient advocate Laurie Adami about CAR-T therapy, an advance cancer treatment that biologically engineers a patient's own T-cells to recognize and kill ca...
ascopubs.org
November 17, 2025 at 8:16 PM
"I was lucky. I had good insurance, I lived in LA, I was treated at 4 big cancer centers.
I speak to patients who if they don't go to work today, they don't get a paycheck. They can't miss a day to travel 8 hours to go see a specialist."
🎙️New @ascocancer.bsky.social @jco-asco.bsky.social podcast:
I speak to patients who if they don't go to work today, they don't get a paycheck. They can't miss a day to travel 8 hours to go see a specialist."
🎙️New @ascocancer.bsky.social @jco-asco.bsky.social podcast:
Check out #JCOGO's new article, discussing implementation of geriatric assessment in resource-constrained settings and some outstanding implementation questions and concerns.
Learn more: brnw.ch/21wXieA
Learn more: brnw.ch/21wXieA
November 7, 2025 at 2:44 PM
Check out #JCOGO's new article, discussing implementation of geriatric assessment in resource-constrained settings and some outstanding implementation questions and concerns.
Learn more: brnw.ch/21wXieA
Learn more: brnw.ch/21wXieA
Check out the article in JCO on the Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Learn about the latest research on this common drug's potential role in managing prostate cancer: brnw.ch/21wX6DG
October 31, 2025 at 6:45 PM
Check out the article in JCO on the Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Learn about the latest research on this common drug's potential role in managing prostate cancer: brnw.ch/21wX6DG